☆ 4.7 Review

Glioblastoma Treatment: State-of-the-Art and Future Perspectives

INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2022)

Related references

Note: Only part of the references are listed.

Article Oncology

ATX-101, a Peptide Targeting PCNA, Has Antitumor Efficacy Alone or in Combination with Radiotherapy in Murine Models of Human Glioblastoma

Giovanni Luca Gravina et al.

Summary: ATX-101, a peptide targeting PCNA, has demonstrated antitumor effects and radiosensitizing properties in glioblastoma multiforme models. This study suggests that ATX-101 could be a promising compound for the treatment of glioblastoma, as it has shown activity in inhibiting tumor growth and sensitizing cells to radiotherapy.

CANCERS (2022)

Add to Collection

Review Clinical Neurology

Advances in local therapy for glioblastoma - taking the fight to the tumour

Thomas S. van Solinge et al.

Summary: This review discusses local therapies for glioblastoma, examining treatment of the resection cavity and other direct approaches to the tumor.

NATURE REVIEWS NEUROLOGY (2022)

Add to Collection

Article Pharmacology & Pharmacy

The Botanical Drug PBI-05204, a Supercritical CO2 Extract of Nerium Oleander, Is Synergistic With Radiotherapy in Models of Human Glioblastoma

Alessandro Colapietro et al.

Summary: The study demonstrates that PBI-05204 enhances the sensitivity of GBM cells to radiation therapy by promoting the transition from autophagy to apoptosis, enhancing DNA damage, and reducing DNA repair. The combination of PBI-05204 with radiotherapy reduces tumor progression and enhances antitumor activity.

FRONTIERS IN PHARMACOLOGY (2022)

Add to Collection

Article Pharmacology & Pharmacy

Development of Lomustine and n-Propyl Gallate Co-Encapsulated Liposomes for Targeting Glioblastoma Multiforme via Intranasal Administration

Gabor Katona et al.

Summary: This study aimed to develop liposomes loaded with lomustine (LOM) and n-propyl gallate (PG) for targeted treatment of glioblastoma multiforme (GBM) through the nose-to-brain drug delivery pathway. The optimized liposomal carrier showed suitable size, distribution, and encapsulation efficiency, overcoming solubility, absorption, and toxicity issues. The combination of LOM and PG in a liposomal formulation holds promise as a carrier for glioblastoma targeting via the intranasal route.

PHARMACEUTICS (2022)

Add to Collection

Review Oncology

A review of glioblastoma immunotherapy

Ravi Medikonda et al.

Summary: Current immunotherapy treatments for glioblastoma, including checkpoint inhibitors and vaccine therapy, have shown disappointing results in clinical trials due to the highly immunosuppressive environment and therapy resistance mechanisms of the tumor. Ongoing research is focusing on exploring combination therapies and novel treatment strategies beyond immune checkpoint therapies, as well as establishing synergy between immunotherapy and current standard of care to improve treatment outcomes. Recent advances in personalized neoantigen vaccines suggest a shift towards personalized, patient-specific treatment for glioblastoma.

JOURNAL OF NEURO-ONCOLOGY (2021)

Add to Collection

Review Oncology

Management of glioblastoma: a perspective from Mexico

Sergio Moreno-Jimenez et al.

Summary: Access to healthcare in Mexico is provided through both publicly and privately funded institutions, with the public sector managed by local and federal government entities. Patients with glioblastoma in Mexico City are primarily treated at the National Institute of Neurology and Neurosurgery and the National Institute of Oncology. Treatment for patients diagnosed with glioblastoma in Mexico is not standardized due to resource constraints and high costs of antineoplastic agents, with options ranging from biopsy only to maximal safe resection followed by adjuvant therapy.

CHINESE CLINICAL ONCOLOGY (2021)

Add to Collection

Article Oncology

EANO guidelines on the diagnosis and treatment of diffuse gliomas of adulthood

Michael Weller et al.

Summary: The European Association of Neuro-Oncology (EANO) has released guidelines for the diagnosis, treatment, and follow-up of adult patients with diffuse gliomas, incorporating major changes in diagnostic algorithms based on the 2016 update of the WHO Classification of Tumors of the Central Nervous System, as well as evidence from recent large clinical trials.

NATURE REVIEWS CLINICAL ONCOLOGY (2021)

Add to Collection

Review Biochemistry & Molecular Biology

Challenges and Perspectives of Standard Therapy and Drug Development in High-Grade Gliomas

Shalini Sundramurthi Chelliah et al.

Summary: High-grade gliomas remain a fatal primary brain tumor, with challenges in standard therapy leading to the need for a multimodal approach that considers environmental and genetic factors affecting treatment response.

MOLECULES (2021)

Add to Collection

Review Clinical Neurology

Chimeric Antigen Receptor T-Cell Therapy: Updates in Glioblastoma Treatment

Lisa Feldman et al.

Summary: CAR T-cell therapy, utilizing genetically engineered cells from patients to target tumor cells, has emerged as a promising strategy for treating GBM. Ongoing clinical trials are exploring the potential of this approach to combat the challenges associated with GBM treatment.

NEUROSURGERY (2021)

Add to Collection

Review Immunology

Current Immunotherapies for Glioblastoma Multiforme

Boyuan Huang et al.

Summary: Glioblastoma multiforme (GBM) is the most common and aggressive malignant tumor in the central nervous system. Immunotherapy has shown promising results in the treatment of GBM, but future developments will require an integrated approach with various treatment modalities and specific targeted therapies for the tumor microenvironment.

FRONTIERS IN IMMUNOLOGY (2021)

Add to Collection

Review Cell Biology

Immunotherapy of Glioblastoma: Current Strategies and Challenges in Tumor Model Development

Bernarda Majc et al.

Summary: Glioblastoma, the most common brain malignant tumor in adults, poses challenges for effective immunotherapy due to its intracranial location, tumor heterogeneity, and immunosuppressive microenvironment. Various promising immunotherapeutic strategies, such as vaccines, oncolytic viruses, immune checkpoint inhibitors, and adoptive cell transfer, have been applied in an attempt to promote tumor eradication and overcome immune resistance. However, discrepancies exist between preclinical studies and clinical studies in evaluating the efficiency of these strategies on glioblastoma patients.

CELLS (2021)

Add to Collection

Article Multidisciplinary Sciences

Intermittent radiotherapy as alternative treatment for recurrent high grade glioma: a modeling study based on longitudinal tumor measurements

Sarah C. Brueningk et al.

Summary: Recurrent high grade glioma patients currently face poor prognosis without a curative treatment option. A personalized treatment strategy involving high dose intermittent radiation treatment (iRT) showed promising results compared to traditional high dose hypofractionated stereotactic radiotherapy (HFSRT) in a simulation analysis, especially for patients responsive to pembrolizumab and bevacizumab. Time to progression could be prolonged through intermittently delivered fractions, making iRT a potential treatment option for recurrent high grade glioma patients.

SCIENTIFIC REPORTS (2021)

Add to Collection

Review Clinical Neurology

Radiotherapy versus combination radiotherapy-bevacizumab for the treatment of recurrent high-grade glioma: a systematic review

Daniel P. Kulinich et al.

Summary: The combination of re-irradiation therapy (reRT) and bevacizumab (BVZ) therapy may improve overall survival (OS) and reduce rates of radiation necrosis (RN) in recurrent high-grade gliomas (HGG) patients. However, further controlled studies are needed to confirm these effects.

ACTA NEUROCHIRURGICA (2021)

Add to Collection

Review Chemistry, Medicinal

Crocetin and related oxygen diffusion-enhancing compounds: Review of chemical synthesis, pharmacology, clinical development, and novel therapeutic applications

Hriday M. Shah et al.

Summary: The current pandemic has led to a reconsideration of oxygen diffusion-enhancing compounds as potential therapeutic agents, particularly in ischemic conditions. TSC, as a first-in-class molecule, is under intense clinical investigation for COVID-19 and shows promise for various diseases. Further research and development in this area may lead to new treatment options for unmet medical needs.

DRUG DEVELOPMENT RESEARCH (2021)

Add to Collection

Review Immunology

Oncolytic Viro-Immunotherapy: An Emerging Option in the Treatment of Gliomas

Jiayi Zeng et al.

Summary: The prognosis of malignant gliomas remains poor, with limited therapeutic options. Immunotherapy and oncolytic virotherapy are rapidly developing fields that hold promise for enhancing cancer treatment effectiveness.

FRONTIERS IN IMMUNOLOGY (2021)

Add to Collection

Review Biochemistry & Molecular Biology

Current status and perspective of CAR-T and CAR-NK cell therapy trials in Germany

Nawid Albinger et al.

Summary: CAR-T cell therapies and CAR-NK cell therapies are powerful immunotherapeutic tools for hematological diseases, with the latter emerging as a novel therapeutic option with advantages over the former. There are currently numerous CAR-T and CAR-NK cell trials being conducted worldwide, offering potential additional choices for clinical applications.

GENE THERAPY (2021)

Add to Collection

Review Biochemistry & Molecular Biology

The Importance of Tumor Stem Cells in Glioblastoma Resistance to Therapy

Vincenzo Mattei et al.

Summary: Glioblastoma (GBM) is a common and lethal brain tumor with high therapy failure rates due to the survival of self-renewing glioblastoma stem cells (GSCs). Targeted therapies may address specific targets essential for GBM cell proliferation, survival, and invasiveness, potentially offering new treatment options.

INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2021)

Add to Collection

Review Oncology

NK Cell-Based Immunotherapy and Therapeutic Perspective in Gliomas

Changqing Pan et al.

Summary: NK cell-based immunotherapy shows promising potential for treating glioma due to its unique features, but faces challenges such as inadequate CAR design and lagging application compared to hematological malignancies. Further strategies are needed to enhance the efficacy of NK cell-based cancer immunotherapy in glioma treatment.

FRONTIERS IN ONCOLOGY (2021)

Add to Collection

Review Immunology

Immunotherapy for Glioblastoma: Current Progress and Challenge

Miranda W. Yu et al.

Summary: Glioblastoma, a highly lethal brain cancer, has brought immunotherapy to the forefront of research, but faces challenges such as resistance, tumor heterogeneity, and immunosuppressive environments. Despite these difficulties, there is active pursuit of more effective immunotherapies for glioblastoma.

FRONTIERS IN IMMUNOLOGY (2021)

Add to Collection

Article Oncology

Lomustine and nimustine exert efficient antitumor effects against glioblastoma models with acquired temozolomide resistance

Shun Yamamuro et al.

Summary: The study demonstrated that CCNU and ACNU have significant antitumor effects against TMZ-resistant GBM, suggesting their potential as effective therapeutic agents in salvage treatment against TMZ-R-GBM.

CANCER SCIENCE (2021)

Add to Collection

Review Neurosciences

Prospects of antibodies targeting CD47 or CD24 in the treatment of glioblastoma

Hao Wu et al.

Summary: Glioma is a highly malignant tumor with limited treatment options, highlighting the importance of seeking effective therapeutic strategies. Research on glioblastoma mainly focuses on immunotherapy and targeted therapy, with CD47/CD24 antibody treatment being a key area of study.

CNS NEUROSCIENCE & THERAPEUTICS (2021)

Add to Collection

Review Biochemistry & Molecular Biology

CAR-NK Cells in the Treatment of Solid Tumors

Ewa Wrona et al.

Summary: CAR-NK cells have emerged as a potential treatment for malignant tumors, offering a lower cost and broader availability for infusion compared to CAR-T cells. Research indicates that CAR-NK cells are effective against both hematological and non-hematological malignancies.

INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2021)

Add to Collection

Review Biochemistry & Molecular Biology

Radiotherapy of High-Grade Gliomas: First Half of 2021 Update with Special Reference to Radiosensitization Studies

Guido Frosina

Summary: This review article discusses the recent advances in radiotherapy for high-grade gliomas during the first half of 2021, highlighting the intensive research being conducted in this field to improve the effectiveness of radiation treatment for these tumors.

INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2021)

Add to Collection

Article Radiology, Nuclear Medicine & Medical Imaging

Bevacizumab in recurrent high-grade glioma: a single institution retrospective analysis on 92 patients

Beatrice Detti et al.

Summary: Overall, the analysis confirms the efficacy of bevacizumab in patients with recurrent high-grade gliomas, with an acceptable toxicity profile. The study found that performance status, age at diagnosis, and the use of corticosteroids during bevacizumab therapy were strongly associated with progression-free survival. Long-term responders accounted for more than half of the cohort.

RADIOLOGIA MEDICA (2021)

Add to Collection

Review Virology

Oncolytic Viruses for Malignant Glioma: On the Verge of Success?

Yogesh R. Suryawanshi et al.

Summary: Glioblastoma is a challenging tumor type to treat with conventional therapy, but immunotherapeutic agents have shown limited success and further optimization is needed. Some oncolytic viruses have demonstrated the ability to infect tumors in malignant glioma patients, but hurdles like the blood-brain barrier and tumor heterogeneity can reduce their efficacy. Strategies are being developed to optimize oncolytic virotherapy outcomes.

VIRUSES-BASEL (2021)

Add to Collection

Article Multidisciplinary Sciences

Oncolytic H-1 parvovirus binds to sialic acid on laminins for cell attachment and entry

Amit Kulkarni et al.

Summary: In-depth understanding of the life cycle of H-1 parvovirus (H-1PV) is crucial for the rational design of combination strategies and development of more effective viruses. The identification of laminin gamma 1 (LAMC1) as a crucial modulator of H-1PV infection highlights the importance of laminin family members in cell attachment and entry. Elevated levels of LAMC1 are found to correlate with increased H-1PV oncolytic activity in various cancer cell lines.

NATURE COMMUNICATIONS (2021)

Add to Collection

Review Neurosciences

CAR T Cell-Based Immunotherapy for the Treatment of Glioblastoma

Luke Maggs et al.

Summary: GBM is the most common and aggressive malignant primary brain tumor in adults, with current treatment options showing limited efficacy. CAR T cell therapy, which involves genetically modifying T cells to target tumor antigens, has shown promise in hematological malignancies but faces challenges in solid tumors due to factors such as the tumor microenvironment and CAR T cell persistence. Nonetheless, research is ongoing to improve the anti-tumor activity of CAR T cells in GBM treatment.

FRONTIERS IN NEUROSCIENCE (2021)

Add to Collection

Review Oncology

Current Immunotherapeutic Strategies for the Treatment of Glioblastoma

Mark Dapash et al.

Summary: This review discusses various immunotherapeutic strategies currently being investigated in the treatment of glioblastoma, including checkpoint inhibitors, vaccination strategies, and CAR T-cell therapy. However, due to the low immunogenicity of the tumor, treatment outcomes remain suboptimal.

CANCERS (2021)

Add to Collection

Review Oncology

Immunotherapy in Glioblastoma: A Clinical Perspective

Nicolas Desbaillets et al.

Summary: Glioblastoma is the most common and aggressive brain tumor, with poor prognosis despite current treatments. Immunotherapies, which have revolutionized cancer treatment for many types of cancer, offer hope for glioblastoma but are facing challenges. Proof of efficacy is still needed, but innovative combinatorial approaches show promise for overcoming limitations in treatment.

CANCERS (2021)

Add to Collection

Review Oncology

CAR-NK Cell: A New Paradigm in Tumor Immunotherapy

Faroogh Marofi et al.

Summary: CAR-NK cells, as an emerging cancer treatment, have various advantages in cancer immunotherapy, including better safety and adaptability, and the ability to improve attack on tumors and eliminate resistance. By targeting different antigens, CAR-NK cells are expected to achieve more effective anti-tumor responses.

FRONTIERS IN ONCOLOGY (2021)

Add to Collection

Review Biotechnology & Applied Microbiology

Prospects of biological and synthetic pharmacotherapies for glioblastoma

David B. Altshuler et al.

EXPERT OPINION ON BIOLOGICAL THERAPY (2020)

Add to Collection

Article Biochemistry & Molecular Biology

Crocetin Extracted from Saffron Shows Antitumor Effects in Models of Human Glioblastoma

Alessandro Colapietro et al.

INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2020)

Add to Collection

Article Oncology

Glioblastoma precision therapy: From the bench to the clinic

Yuan Zhou et al.

CANCER LETTERS (2020)

Add to Collection

Article Oncology

Effect of Nivolumab vs Bevacizumab in Patients With Recurrent Glioblastoma The CheckMate 143 Phase 3 Randomized Clinical Trial

David A. Reardon et al.

JAMA ONCOLOGY (2020)

Add to Collection

Review Oncology

Management of glioblastoma: State of the art and future directions

Aaron C. Tan et al.

CA-A CANCER JOURNAL FOR CLINICIANS (2020)

Add to Collection

Review Oncology

How did lomustine become standard of care in recurrent glioblastoma?

Michael Weller et al.

CANCER TREATMENT REVIEWS (2020)

Add to Collection

Review Biochemistry & Molecular Biology

Oncolytic Virotherapy in Glioma Tumors

Sergio Rius-Rocabert et al.

INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2020)

Add to Collection

Article Pharmacology & Pharmacy

The Botanical Drug PBI-05204, a Supercritical CO2Extract of Nerium Oleander, Inhibits Growth of Human Glioblastoma, Reduces Akt/mTOR Activities, and Modulates GSC Cell-Renewal Properties

Alessandro Colapietro et al.

FRONTIERS IN PHARMACOLOGY (2020)

Add to Collection

Review Immunology

Glioblastoma Immune Landscape and the Potential of New Immunotherapies

Thomas Daubon et al.

FRONTIERS IN IMMUNOLOGY (2020)

Add to Collection

Review Oncology

Radiation Effects on Brain Extracellular Matrix

Elvira V. Grigorieva

FRONTIERS IN ONCOLOGY (2020)

Add to Collection

Review Immunology

Treatment Progress of Immune Checkpoint Blockade Therapy for Glioblastoma

Na Zhang et al.

FRONTIERS IN IMMUNOLOGY (2020)

Add to Collection

Article Oncology

Effect of Vocimagene Amiretrorepvec in Combination With Flucytosine vs Standard of Care on Survival Following Tumor Resection in Patients With Recurrent High-Grade Glioma A Randomized Clinical Trial

Timothy F. Cloughesy et al.

JAMA ONCOLOGY (2020)

Add to Collection

Review Chemistry, Medicinal

The Landscape of Novel Therapeutics and Challenges in Glioblastoma Multiforme: Contemporary State and Future Directions

Karam Khaddour et al.

PHARMACEUTICALS (2020)

Add to Collection

Review Immunology

Chimeric Antigen Receptor T-Cell Therapy in Glioblastoma: Current and Future

Long Li et al.

FRONTIERS IN IMMUNOLOGY (2020)

Add to Collection

Review Oncology

Central Nervous System Cancers Version 3.2020

Louis Burt Nabors et al.

JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK (2020)

Add to Collection

Article Oncology

Pilot Trial of Adoptive Transfer of Chimeric Antigen Receptor-transduced T Cells Targeting EGFRvIII in Patients With Glioblastoma

Stephanie L. Goff et al.

JOURNAL OF IMMUNOTHERAPY (2019)

Add to Collection

Article Medicine, General & Internal

Lomustine-temozolomide combination therapy versus standard temozolomide therapy in patients with newly diagnosed glioblastoma with methylated MGMT promoter (CeTeG/NOA-09): a randomised, open-label, phase 3 trial

Ulrich Herrlinger et al.

LANCET (2019)

Add to Collection

Review Oncology

Updates to the antitumor mechanism of oncolytic virus

Yang Bai et al.

THORACIC CANCER (2019)

Add to Collection

Article Oncology

The Small Molecule Ephrin Receptor Inhibitor, GLPG1790, Reduces Renewal Capabilities of Cancer Stem Cells, Showing Anti-Tumour Efficacy on Preclinical Glioblastoma Models

Giovanni Luca Gravina et al.

CANCERS (2019)

Add to Collection

Review Oncology

Molecular targeted therapy of glioblastoma

Emilie Le Rhun et al.

CANCER TREATMENT REVIEWS (2019)

Add to Collection

Article Oncology

The Brain Penetrating and Dual TORC1/TORC2 Inhibitor, RES529, Elicits Anti-Glioma Activity and Enhances the Therapeutic Effects of Anti-Angiogenetic Compounds in Preclinical Murine Models

Giovanni Luca Gravina et al.

CANCERS (2019)

Add to Collection

Article Oncology

Novel Immunotherapeutics for Treatment of Glioblastoma: The Last Decade of Research

Emaad Khansur et al.

CANCER INVESTIGATION (2019)

Add to Collection

Article Multidisciplinary Sciences

Actively personalized vaccination trial for newly diagnosed glioblastoma

Norbert Hilf et al.

NATURE (2019)

Add to Collection

Article Multidisciplinary Sciences

Neoantigen vaccine generates intratumoral T cell responses in phase Ib glioblastoma trial

Derin B. Keskin et al.

NATURE (2019)

Add to Collection

Review Biotechnology & Applied Microbiology

Vaccination in the immunotherapy of glioblastoma

Ziren Kong et al.

HUMAN VACCINES & IMMUNOTHERAPEUTICS (2018)

Add to Collection

Review Anesthesiology

Anesthesia for awake craniotomy

Alexander Kulikov et al.

CURRENT OPINION IN ANESTHESIOLOGY (2018)

Add to Collection

Article Medicine, Research & Experimental

First results on survival from a large Phase 3 clinical trial of an autologous dendritic cell vaccine in newly diagnosed glioblastoma

Linda M. Liau et al.

JOURNAL OF TRANSLATIONAL MEDICINE (2018)

Add to Collection

Article Oncology

Temozolomide for immunomodulation in the treatment of glioblastoma

Aida Karachi et al.

NEURO-ONCOLOGY (2018)

Add to Collection

Article Medicine, General & Internal

Recurrent Glioblastoma Treated with Recombinant Poliovirus

Annick Desjardins et al.

NEW ENGLAND JOURNAL OF MEDICINE (2018)

Add to Collection

Article Oncology

Anesthesia for Awake Craniotomy for Brain Tumors in an Intraoperative MRI Suite: Challenges and Evidence

Tumul Chowdhury et al.

FRONTIERS IN ONCOLOGY (2018)

Add to Collection

Review Clinical Neurology

Current and future strategies for treatment of glioma

Nancy Ann Oberheim Bush et al.

NEUROSURGICAL REVIEW (2017)

Add to Collection

Article Medicine, General & Internal

Effect of Tumor-Treating Fields Plus Maintenance Temozolomide vs Maintenance Temozolomide Alone on Survival in Patients With Glioblastoma A Randomized Clinical Trial

Roger Stupp et al.

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2017)

Add to Collection

Editorial Material Clinical Neurology

Comparison of Conscious Sedation and Asleep-Awake-Asleep Techniques for Awake Craniotomy

Ozlem Korkmaz Dilmen et al.

JOURNAL OF CLINICAL NEUROSCIENCE (2017)

Add to Collection

Article Clinical Neurology

Trans sodium crocetinate with temozolomide and radiation therapy for glioblastoma multiforme

John L. Gainer et al.

JOURNAL OF NEUROSURGERY (2017)

Add to Collection

Article Oncology

Rindopepimut with temozolomide for patients with newly diagnosed, EGFRvIII-expressing glioblastoma (ACT IV): a randomised, double-blind, international phase 3 trial

Michael Weller et al.

LANCET ONCOLOGY (2017)

Add to Collection

Review Clinical Neurology

Vaccine-based immunotherapeutic approaches to gliomas and beyond

Michael Weller et al.

NATURE REVIEWS NEUROLOGY (2017)

Add to Collection

Article Clinical Neurology

Fluorescence Imaging/Agents in Tumor Resection

Walter Stummer et al.

NEUROSURGERY CLINICS OF NORTH AMERICA (2017)

Add to Collection

Article Cell Biology

A single dose of peripherally infused EGFRvIII-directed CAR T cells mediates antigen loss and induces adaptive resistance in patients with recurrent glioblastoma

Donald M. O'Rourke et al.

SCIENCE TRANSLATIONAL MEDICINE (2017)

Add to Collection

Review Pharmacology & Pharmacy

Immune Checkpoint in Glioblastoma: Promising and Challenging

Jing Huang et al.

FRONTIERS IN PHARMACOLOGY (2017)

Add to Collection

Review Immunology

Advances in Immunotherapy for Glioblastoma Multiforme

Boyuan Huang et al.

JOURNAL OF IMMUNOLOGY RESEARCH (2017)

Add to Collection

Article Oncology

HER2-Specific Chimeric Antigen Receptor-Modified Virus-Specific T Cells for Progressive Glioblastoma A Phase 1 Dose-Escalation Trial

Nabil Ahmed et al.

JAMA ONCOLOGY (2017)

Add to Collection

Review Oncology

Mechanisms of action and rationale for the use of checkpoint inhibitors in cancer

Clemence Granier et al.

ESMO OPEN (2017)

Add to Collection

Review Oncology

Glioblastoma targeted therapy: updated approaches from recent biological insights

M. Touat et al.

ANNALS OF ONCOLOGY (2017)

Add to Collection

Review Oncology

Advances in Experimental Targeted Therapy and Immunotherapy for Patients with Glioblastoma Multiforme

Jiri Polivka et al.

ANTICANCER RESEARCH (2017)

Add to Collection

Review Oncology

RES-529: a PI3K/AKT/mTOR pathway inhibitor that dissociates the mTORC1 and mTORC2 complexes

Mark A. Weinberg

ANTI-CANCER DRUGS (2016)

Add to Collection

Review Oncology

Maximizing safe resection of low- and high-grade glioma

Shawn L. Hervey-Jumper et al.

JOURNAL OF NEURO-ONCOLOGY (2016)

Add to Collection

Article Oncology

Glioblastoma: Overview of Disease and Treatment

Mary Elizabeth Davis

CLINICAL JOURNAL OF ONCOLOGY NURSING (2016)

Add to Collection

Review Biotechnology & Applied Microbiology

Oncolytic viruses: a new class of immunotherapy drugs

Howard L. Kaufman et al.

NATURE REVIEWS DRUG DISCOVERY (2015)

Add to Collection

Article Oncology

A phase II, multicenter trial of rindopepimut (CDX-110) in newly diagnosed glioblastoma: the ACT III study

James Schuster et al.

NEURO-ONCOLOGY (2015)

Add to Collection

Meeting Abstract Oncology

RE-ANALYSIS OF PFS/RESPONSE USING ORIGINAL MACDONALD CRITERIA AND RESPONSE EVALUATION CRITERIA IN SOLID TUMORS IN THE PHASE III AVAGLIO STUDY OF BEVACIZUMAB PLUS RADIOTHERAPY AND TEMOZOLOMIDE IN NEWLY DIAGNOSED GLIOBLASTOMA

Olivier L. Chinot et al.

NEURO-ONCOLOGY (2014)

Add to Collection

Article Clinical Neurology

Isocitrate dehydrogenase status and molecular subclasses of glioma and glioblastoma

Sameer Agnihotri et al.

NEUROSURGICAL FOCUS (2014)

Add to Collection

Article Medicine, General & Internal

A Randomized Trial of Bevacizumab for Newly Diagnosed Glioblastoma

Mark R. Gilbert et al.

NEW ENGLAND JOURNAL OF MEDICINE (2014)

Add to Collection

Letter Medicine, General & Internal

Bevacizumab for Newly Diagnosed Glioblastoma Reply

Olivier L. Chinot et al.

NEW ENGLAND JOURNAL OF MEDICINE (2014)

Add to Collection

Article Medicine, General & Internal

Bevacizumab plus Radiotherapy-Temozolomide for Newly Diagnosed Glioblastoma

Olivier L. Chinot et al.

NEW ENGLAND JOURNAL OF MEDICINE (2014)

Add to Collection

Article Clinical Neurology

Technical principles and neurosurgical applications of fluorescein fluorescence using a microscope-integrated fluorescence module

Roberto Rey-Dios et al.

ACTA NEUROCHIRURGICA (2013)

Add to Collection

Article Oncology

Disruption of Wild-Type IDH1 Suppresses D-2-Hydroxyglutarate Production in IDH1-Mutated Gliomas

Genglin Jin et al.

CANCER RESEARCH (2013)

Add to Collection

Article Pharmacology & Pharmacy

RINDOPEPIMUT Anti-EGFRvIII Peptide Vaccine Oncolytic

Patrick C. Gedeon et al.

DRUGS OF THE FUTURE (2013)

Add to Collection

Review Biochemistry & Molecular Biology

The epidermal growth factor receptor variant III (EGFRvIII): where wild things are altered

Hui K. Gan et al.

FEBS JOURNAL (2013)

Add to Collection

Review Oncology

Oncolytic Virus Therapy for Glioblastoma Multiforme Concepts and Candidates

Guido Wollmann et al.

CANCER JOURNAL (2012)

Add to Collection

Review Clinical Neurology

Aminolevulinic acid (ALA)-protoporphyrin IX fluorescence guided tumour resection. Part 2: Theoretical, biochemical and practical aspects

Michael J. Colditz et al.

JOURNAL OF CLINICAL NEUROSCIENCE (2012)

Add to Collection

Article Multidisciplinary Sciences

IDH1 mutation is sufficient to establish the glioma hypermethylator phenotype

Sevin Turcan et al.

NATURE (2012)

Add to Collection

Article Multidisciplinary Sciences

IDH1(R132H) mutation increases murine haematopoietic progenitors and alters epigenetics

Masato Sasaki et al.

NATURE (2012)

Add to Collection

Article Biochemical Research Methods

Metabolomic Patterns in Glioblastoma and Changes during Radiotherapy: A Clinical Microdialysis Study

Carl Wibom et al.

JOURNAL OF PROTEOME RESEARCH (2010)

Add to Collection

Review Oncology

MGMT promoter methylation in malignant gliomas

Markus J. Riemenschneider et al.

TARGETED ONCOLOGY (2010)

Add to Collection

Article Cell Biology

Identification of a novel, widespread, and functionally important PCNA-binding motif

Karin M. Gilljam et al.

JOURNAL OF CELL BIOLOGY (2009)

Add to Collection

Article Oncology

An epidermal growth factor receptor variant III-targeted vaccine is safe and immunogenic in patients with glioblastoma multiforme

John H. Sampson et al.

MOLECULAR CANCER THERAPEUTICS (2009)

Add to Collection

Article Oncology

Fluorescence-guided surgery with 5-aminolevulinic acid for resection of malignant glioma: a randomised controlled multicentre phase III trial

W Stummer et al.

LANCET ONCOLOGY (2006)

Add to Collection

Article Medicine, General & Internal

Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma

R Stupp et al.

NEW ENGLAND JOURNAL OF MEDICINE (2005)

Add to Collection

Review Oncology

Current management of glioblastoma multiforme

SA Grossman et al.

SEMINARS IN ONCOLOGY (2004)

Add to Collection

Article Oncology

Abbreviated course of radiation therapy in older patients with glioblastoma multiforme: A prospective randomized clinical trial

W Roa et al.

JOURNAL OF CLINICAL ONCOLOGY (2004)

Add to Collection

Article Clinical Neurology

A multivariate analysis of 416 patients with glioblastoma multiforme: prognosis, extent of resection, and survival

M Lacroix et al.

JOURNAL OF NEUROSURGERY (2001)

Add to Collection

© Peeref 2019-2024. All rights reserved.